Microwave Ablation Feasible for T1N0M0 Papillary Thyroid Carcinoma
By Elana Gotkine HealthDay Reporter
FRIDAY, April 12, 2024 -- For patients with multifocal papillary thyroid carcinoma (PTC), the rates of progression-free survival (PFS) do not differ between microwave ablation (MWA) and surgical resection (SR), according to a study published online April 2 in Radiology.
Zhen-Long Zhao, M.D., from the China-Japan Friendship Hospital in Beijing, and colleagues compared MWA and SR for preoperative ultrasound-detected T1N0M0 multifocal PTC in terms of overall and one-, three-, and five-year PFS rates in a retrospective study. Data were included for 775 patients.
After propensity score matching, 229 and 453 patients in the MWA and SR groups were observed for a median of 20 and 26 months, respectively. The researchers found less blood loss, shorter incision length, and shorter procedure and hospitalization durations in the MWA group. No evidence of differences in overall and one-, three-, or five-year PFS rates were seen between MWA and SR (five-year rate, 77.2 and 83.1 percent, respectively). In the SR group only, permanent hoarseness and hypoparathyroidism were encountered.
"MWA may be a promising option in the treatment of multifocal PTC, and further validation through prospective studies is recommended to solidify the role of MWA in the treatment paradigm of multifocal PTC," the authors write.
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted April 2024
Read this next
American College of Surgeons, Oct. 19-22
The annual meeting of the American College of Surgeons was held this year from Oct. 19 to 22 in San Francisco and attracted participants from around the world, including...
Clinicians Often Fail to Rescue Women With Complications After High-Risk Surgery
TUESDAY, Oct. 29, 2024 -- Clinicians fail to rescue female patients with complications after high-risk vascular and cardiac surgeries more often than male patients, according to a...
Trends in Obesity Treatment Show Surge in GLP-1 RAs, Drop in Surgeries
TUESDAY, Oct. 29, 2024 -- Among privately insured patients, there was a doubling in the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as antiobesity treatment from...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.